Loading...
•
Mar 31, 2022
MacroGenics Q1 2022 Earnings Report
Reported financial results for the quarter ended March 31, 2022 and provided update on corporate progress.
Key Takeaways
MacroGenics reported first quarter 2022 financial results, with total revenue of $11.1 million, including $3.6 million in MARGENZA sales. The company's net loss was $66.4 million. They plan to start Phase 2/3 prostate cancer study with MGC018 by year-end and initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors.
Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end.
Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors.
Targeting mid-2022 start of Phase 1 study of MGD024 in hematologic malignancies.
FDA accepted the Biologics License Application (BLA) for teplizumab for the delay of clinical T1D in at-risk individuals.
Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...